Chenivesse X, Franco D, Bréchot C
INSERM U75, C.H.U. Necker, Paris, France.
J Hepatol. 1993 Jun;18(2):168-72. doi: 10.1016/s0168-8278(05)80243-0.
MDR1 RNA levels were analysed in patients with hepatocellular carcinoma (HCC), benign liver tumors or cirrhosis. None of the patients with HCC had received chemotherapy. MDR1 RNA levels were increased relative to a normal liver specimen in 15/26 liver cancers, 2/6 benign liver tumors and 0/8 tumor-free cirrhotic livers. MDR1 was also overexpressed in cirrhotic non-tumorous liver tissues of some patients with HCC. The results indicate that the MDR1 gene is overexpressed in liver tumors and some preneoplastic lesions and that might account for the very poor response of primary liver cancers to chemotherapy.
对肝细胞癌（HCC）、良性肝肿瘤或肝硬化患者的多药耐药蛋白1（MDR1）RNA水平进行了分析。所有HCC患者均未接受过化疗。相对于正常肝脏标本，26例肝癌中有15例、6例良性肝肿瘤中有2例、8例无肿瘤肝硬化肝脏中有0例的MDR1 RNA水平升高。MDR1在一些HCC患者的肝硬化非肿瘤性肝组织中也有过表达。结果表明，MDR1基因在肝肿瘤和一些癌前病变中过表达，这可能是原发性肝癌对化疗反应极差的原因。
